0
From the Guest Editors
Peter F. Buckley, M.D.; Brian J. Miller, M.D., Ph.D., M.P.H.
CME   Is Relapse in Schizophrenia an Immune-Mediated Effect?
Brian J. Miller, M.D., Ph.D., M.P.H.; Peter F. Buckley, M.D.
CME   Antipsychotic Medication Nonadherence: Risk Factors and Remedies
Oliver Freudenreich, M.D.; Corinne Cather, Ph.D.
CME   Managing Medication Effects on Body Weight: Do Behavioral Interventions Work?
Joseph C. Ratliff, Ph.D.; Erin L. Reutenauer, B.A.; Cenk Tek, M.D.
CME   Comorbid Alcohol, Cannabis, and Cocaine Use Disorders in Schizophrenia: Epidemiology, Consequences, Mechanisms, and Treatment
Peter H. Addy, Ph.D.; Rajiv Radhakrishnan, M.D.; Jose A. Cortes, M.S.; Deepak Cyril D’Souza, M.D.
Ask the Expert: Schizophrenia
Christoph U. Correll, M.D.
Performance in PracticePhysician Practice Assessment Tool for the Care of Adults With Schizophrenia
Farifteh F. Duffy, Ph.D.; Joyce C. West, Ph.D., M.P.P.; Laura J. Fochtmann, M.D.; Lisa Dixon, M.D., M.P.H.; Julie Kreyenbuhl, Pharm D., Ph.D.; Eve K. Mościcki, Sc.D., M.P.H.; Robert Plovnick, M.D., M.S.; Robert Kunkle, M.A.
The 2009 Schizophrenia PORT Psychopharmacological Treatment Recommendations and Summary Statements
Robert W. Buchanan; Julie Kreyenbuhl; Deanna L. Kelly; Jason M. Noel; Douglas L. Boggs; Bernard A. Fischer; Seth Himelhoch; Beverly Fang; Eunice Peterson; Patrick R. Aquino; William Keller
Evidence-Based Psychotherapy for Schizophrenia 2011 Update
Faith B. Dickerson, Ph.D., M.P.H.; Anthony F. Lehman, M.D., M.S.P.H.
The NIMH-CATIE Schizophrenia Study: What Did We Learn?
Jeffrey A. Lieberman, M.D.; T. Scott Stroup, M.D., M.P.H.
Risperidone Nonadherence and Return of Positive Symptoms in the Early Course of Schizophrenia
Kenneth L. Subotnik, Ph.D.; Keith H. Nuechterlein, Ph.D.; Joseph Ventura, Ph.D.; Michael J. Gitlin, M.D.; Stephen Marder, M.D.; Jim Mintz, Ph.D.; Gerhard S. Hellemann, Ph.D.; Leslie A. Thornton, Ph.D.; Indira R. Singh, B.S.
Perspectives on Systems of Care
Marvin S. Swartz, M.D.